Is PP405 the Answer to Hair Loss?

Last reviewed February 2026

PP405 (Pelage Pharmaceuticals) is an investigational topical small molecule designed to
reactivate dormant hair follicle stem cells by shifting follicle metabolism
(mitochondrial pyruvate carrier (MPC) inhibition → increased reliance on glycolytic pathways).

Pelage reported topline results from a randomized, vehicle-controlled Phase 2a trial
(Jun 17, 2025): the study met its primary safety endpoint and reported
no detectable systemic absorption in blood on pharmacokinetic testing. In a reported responder subset,
~31% of men with more advanced androgenetic alopecia achieved >20% hair density increase at ~8 weeks
versus 0% in placebo.

Pelage raised a $120M Series B in October 2025 and has indicated Phase 3 studies are planned for 2026.

Pattern hair loss—especially androgenetic alopecia—affects millions of men and women worldwide. While traditional therapies like minoxidil and finasteride have been available for decades, many hair loss patients seek safer, more targeted solutions. A promising new topical small molecule compound, PP405, has emerged as a frontrunner in the search for a drug that can spark new hair growth by directly stimulating human hair follicle stem cells.

Developed by Pelage Pharmaceuticals, a medical development company spun out of research at UCLA, PP405 is in clinical development for the treatment of androgenetic alopecia. Early topline data suggest it may offer a meaningful new direction for patients who want a localized, non-hormonal approach—though longer and larger trials will determine durability, breadth of response, and real-world hair regrowth performance.

What Is PP405 (the UCLA-derived topical)?

PP405 is a topical small molecule that bypasses hormonal pathways and targets metabolic signaling inside the follicle. Specifically, it inhibits the mitochondrial pyruvate carrier (MPC)—a protein that controls how pyruvate enters the mitochondria for energy generation. By disrupting this pathway, PP405 shifts cells toward glycolysis, a state associated with tissue regeneration and stem cell activation.

Pelage’s clinical study record is available publicly here:
View the Phase 2a ClinicalTrials.gov study record (NCT06393452).

Media Spotlight: PP405 Sparks Global Buzz

In August 2025, New York Magazine / Intelligencer ran a feature titled
“The Great Unbalding Draws Nearer”
that quickly went viral. Rather than dissecting trial data, the piece explored how one experimental compound can ignite worldwide hope, fuel online debates, and inspire memes about the possible “end of baldness.”

From Reddit’s Tressless forum to mainstream news outlets, the conversation around PP405 shows that hair restoration breakthroughs don’t just live in laboratories — they shape culture, identity, and optimism in real time.

About Pelage Pharma

Drs. William Lowry and Heather Christofk, together with Dr. Michael Jung (medicinal chemist), co-founded Pelage Pharma. They are joined by Daniel Gil, Ph.D. (CEO) and Qing Yu Christina Weng, M.D. (CMO). Pelage has raised multiple rounds of financing, including a $120M Series B announced in October 2025 to support advancement of PP405 toward Phase 3 in 2026.

Study Update

Pelage’s Phase 2a program (NCT06393452) was a two-part study design: a randomized, double-blind, vehicle-controlled portion followed by an open-label extension intended to validate results with longer treatment exposure. The public topline announcement (Jun 17, 2025) reported primary safety success, pharmacokinetic findings consistent with localized topical use (no detectable systemic absorption in blood), and a responder subset result in men with more advanced androgenetic alopecia.

A Parallel Innovation: TR6 Botanical Complex

While PP405 advances through traditional pharmaceutical channels, AlviArmani Research Institute has spent nearly two decades developing a biologically active alternative: the TR6™ Botanical Complex.
TR6 is the result of a long-term effort to identify, test, and dose-optimize phytonutrients capable of awakening dormant follicles using a natural, non-pharmaceutical route.

Research began in 2006 with hundreds of botanicals cited in ancient medicine. These were formulated into topicals and tested using
MicroScalp™ Technology,
AlviArmani’s proprietary hair follicle viability assay. Over 20,000 grafts were studied.

Where PP405 works through mitochondrial signaling, TR6 optimizes multiple processes involved in hair growth cycling to achieve a similar outcome: enhanced follicular activity and increased visible density across various hair types and skin types. It’s the botanical foundation behind
Sempre Hair Growth Shampoo & Conditioner
and perioperative kits used to support patients before and after transplant procedures.

How Does Pelage Pharmaceuticals PP405 Work?

What Do Hair Follicles and Leg Day Have in Common?

Think back to the burn in your legs during a hard workout — that’s your muscles switching from oxygen-powered (aerobic) metabolism to glycolysis, a faster, oxygen-independent way of producing energy.

Interestingly, regenerating hair follicle stem cells can favor similar metabolic patterns when they’re preparing to activate.

PP405 aims to mimic that “activation state.” By inhibiting the mitochondrial pyruvate carrier (MPC), PP405 nudges dormant hair follicle stem cells away from mitochondrial metabolism and toward glycolysis—potentially helping them exit dormancy.

PP405 pushes hair follicle stem cells into “go mode” by reprogramming their metabolism — similar to how your body shifts pathways when it needs rapid output.

How Does PP405 Affect The Hair Growth Cycle?

PP405 is intended to support the shift from telogen (rest) toward anagen (growth) by targeting follicle stem cell biology. If the mechanism holds up in longer trials, the promise is visible density gains without systemic hormone disruption. As with any investigational therapy, the key unknowns remain durability, breadth of response, and performance across hair types and stages of loss.

Understanding the Science Behind Both Approaches

Hair follicles cycle through growth, rest, and shedding phases. When human hair follicle stem cells become quiescent—due to aging, metabolic imbalance, or damage—hair stops regenerating. A 2017 study in Nature Cell Biology found that increasing lactate dehydrogenase activity could reactivate stem cells, promoting regrowth (Flores et al., 2017). PP405’s mechanism attempts to leverage related metabolic biology.

In parallel, TR6 was refined through a process of formulation, breakdown, retesting, and dose optimization. Unlike pharmaceutical interventions,

Unlike pharmaceutical interventions, TR6 is not pursuing a path of FDA approval and leverages a botanical strategy that has high levels of patient tolerance and compliance. (TR6 may include anti-DHT activity as one of its modes of action and is not appropriate for expecting or nursing mothers.)

Learn more about our non-surgical restoration therapies, which integrate
TR6-based kits,
PRP, and exosomes, often in preparation for or in conjunction with surgical procedures.

Why It Matters

1. Topical, Localized Action – Both PP405 and TR6 act directly at the scalp, limiting systemic exposure.
2. Diverse Applicability – Designed for broad applicability across many hair types and skin types.
3. Alternative to Hormones – Unlike finasteride, both can operate independently of systemic hormonal pathways (TR6 contains anti-DHT activity as one component; topical use helps limit systemic exposure).
4. Innovative Science – TR6 is a leader in botanical multi-pathway formulation; PP405 represents a pharmacologic approach to stem cell metabolism.
5. Complementary Use – Patients using TR6-based products may benefit further from PP405 once clinically validated and approved.
6. Not Appropriate For – Neither will likely be significantly effective for higher degree of hair loss and bald areas due to follicular scarring.

Check out Sempre Hair Growth Products (TR6™) →

What Does The Early Clinical Data on PP405 Show?

Pelage’s topline Phase 2a announcement reported primary safety success and measurable hair density improvement in a responder subset. The larger story is that PP405 is a rare example of an investigational AGA drug that is attempting to “switch on” follicle biology through metabolism rather than hormone blockade.

Understanding FDA Clinical Trial Phases

Tap to expand: how new drugs move through FDA phases

For a new pharmaceutical like PP405 to reach the public in the United States, it must undergo a multi-phase review process overseen by the U.S. Food and Drug Administration (FDA). Each phase is designed to assess the drug’s safety, dose, pharmacokinetics, and efficacy in progressively larger and more diverse patient populations.

1. Phase 1: Basic safety, tolerability, and pharmacokinetics in a small group.
2. Phase 2a: Dose-ranging + early signs of effectiveness in a target population.
3. Phase 2b: Larger efficacy and safety confirmation.
4. Phase 3: Large, multicenter trials vs placebo or standard of care, used for approval decisions.

PP405 is in Phase 2a development, with Phase 3 planned for 2026 per Pelage’s financing announcement.

Why AlviArmani Did Not Pursue the FDA Route with TR6

While PP405 follows the FDA drug approval pathway, AlviArmani made a conscious decision not to pursue FDA clearance for TR6. This choice was based on a core belief: hair loss is a multi-factor condition that rarely yields to a single-agent, single-target model.

Hair cycling involves multiple interdependent biological processes—including metabolism, inflammation, hormonal signaling, extracellular matrix dynamics, and vascular supply. TR6 was created with this complexity in mind: a synergistic, dose-optimized blend of phytonutrients tested over years using advanced assays including MicroScalp™ and PCR gene analysis.

At AlviArmani, our philosophy is simple: treat the root causes of hair loss with scientifically rigorous, patient-aligned solutions—whether surgical, botanical, or metabolic. That’s why TR6 is integrated into every phase of our hair transplant process, from pre-op optimization to post-op regrowth support.

Learn more about our scientific advancements and how they inform every product and procedure we offer.

Why So Many Hair Loss Drugs Fail

The road to regulatory approval is long—and filled with failure. While PP405 shows promise, many hair loss programs stall due to limited efficacy, safety/tolerability challenges, or difficulties translating early signals into durable, real-world outcomes.

Snapshot: investigational + approved therapies (AGA and AA)

Company / Program	Status	Notes	Source
Pelage Pharmaceuticals — PP405	Ongoing (AGA)	Topical MPC inhibitor; Phase 2a topline reported (safety met; responder subset density gains); Phase 3 planned for 2026.	Pelage topline release / NCT06393452
Veradermics — VDPHL01	Ongoing (AGA)	Investigational extended-release oral minoxidil platform; Phase 2/3 & Phase 3 trials described by company.	Veradermics update
Eirion Therapeutics — ET-02	Early clinical (AGA)	Topical candidate; company reported “first-in-man” clinical results and plans further development.	PR Newswire (Eirion)
Amplifica — AMP-303	Early clinical (AGA)	Injectable candidate; company described placebo-controlled clinical outcomes after a single treatment cycle.	Amplifica update
RepliCel — RCH-01 (cell therapy)	Legacy / unclear	Autologous cell-therapy concept; company has undergone major corporate changes and asset transactions; current AGA development status is uncertain.	RepliCel corporate update
Eli Lilly / Incyte — baricitinib (Olumiant)	Approved (AA)	FDA-approved systemic treatment for severe alopecia areata (not AGA).	Lilly press release
Pfizer — ritlecitinib (Litfulo)	Approved (AA)	FDA-approved for adults and adolescents (12+) with severe alopecia areata (not AGA).	Pfizer press release
Setipiprant (PTGDR2 antagonist)	Failed efficacy (AGA)	Randomized Phase 2a in male AGA: safe/well tolerated but did not demonstrate efficacy vs placebo for scalp hair growth.	Peer-reviewed Phase 2a paper
Aclaris Therapeutics — ATI-502 (topical JAK inhibitor)	Discontinued (AA)	Company reported Phase 2 did not meet endpoints; development for AA discontinued.	Aclaris release
Biosplice (Samumed) — SM04554 (dalosirvat)	Stalled / unclear	Wnt-pathway modulator program with trials registered; public development updates have been limited in recent years.	NCT03742518
Intercytex / Aderans (hair multiplication)	Discontinued	Earlier “hair cloning/multiplication” efforts ultimately discontinued after inconsistent results and/or funding ended.	Tressless overview

This high attrition rate underscores why we’re careful with hype. PP405 is promising—but still investigational. TR6 is available now and already integrated clinically alongside PRP, exosomes, and Vitruvian FUE™ to improve the scalp environment and support outcomes.

Looking for trial timelines and what’s real vs hype? Visit the
Hair Loss Treatment News 2025 hub.

For more breakthrough hair loss solutions →

Looking Ahead

As the scientific understanding of hair growth advances, PP405 represents a metabolically targeted drug approach, while TR6 continues to deliver results through a multi-pathway botanical strategy grounded in years of clinical use.

Have all our prayers been answered for hair loss? Not yet. But the momentum is real—and the next decade should bring more credible options than the last three.

At AlviArmani, our mission is to combine the best of both worlds: scientific rigor and real-world applicability. Whether it’s TR6, advanced regenerative techniques, or personalized surgical artistry, we believe in giving patients a comprehensive toolkit—not just a single molecule.

To learn more about AlviArmani advancements click here →

If you would like a personal assessment for hair loss solutions →

---

PP405 FAQ (What Patients Ask Most)

Important note: PP405 is investigational and not FDA-approved. Information below reflects publicly available trial descriptions and topline summaries, and it may change as new data are released. Always consult a qualified clinician for personal guidance.

What is PP405?

PP405 is an investigational topical small-molecule being developed for androgenetic alopecia (pattern hair loss).
The goal is to promote new visible hair growth by reactivating dormant hair follicle stem cells through a metabolic mechanism.

How does PP405 work (in plain English)?

PP405 is designed to shift hair follicle cells into a metabolic “activation” state by inhibiting the mitochondrial pyruvate carrier (MPC).
That shift increases reliance on glycolytic pathways, which are associated with tissue regeneration and stem cell activation.
The theory: if a follicle is dormant (not dead), it may be nudged back into growth.

Is PP405 FDA-approved? Can I get it now?

No. PP405 is not FDA-approved and is currently only available through clinical trials (if enrolling).
Until approval, it cannot be marketed or prescribed as a standard treatment.

What did the Phase 2a trial show?

In topline reporting, Pelage stated the Phase 2a program met its primary safety endpoint and reported
no detectable systemic absorption in blood on pharmacokinetic testing. A reported responder subset in men with
more advanced androgenetic alopecia achieved >20% hair density increase at ~8 weeks versus 0% in placebo.
Full datasets, durability curves, and subgroup details typically come later via scientific presentations/publications.

Does PP405 replace minoxidil or finasteride?

Not yet. Because PP405 is investigational, it should be viewed as a potential future option rather than a replacement.
If approved, it could become an additional tool—especially for patients seeking a non-hormonal, localized approach.

Who is the “best fit” patient for PP405 (if it works as intended)?

Most regenerative topicals work best when follicles are dormant but still present.
In practice, that often means:

• Early to moderate androgenetic alopecia
• Miniaturization present (thinning) rather than fully smooth, long-standing bald scalp
• Patients wanting localized action and to avoid systemic hormone disruption

End-stage balding areas can be harder to reverse if follicles have been lost or scarred.

Will PP405 work for women?

The Phase 2a record describes enrollment of both men and women, but widely shared topline highlights often focus on a male subset.
The most important “next step” for women is the release of full subgroup results (density change distributions, durability, and tolerability).

What about side effects and safety?

In topline reporting, PP405 was described as meeting primary safety endpoints, and pharmacokinetic testing was described
as showing no detectable systemic absorption in blood. As with any topical under investigation, common areas to watch include:

• Scalp irritation, dryness, itching, or redness
• Contact dermatitis in sensitive users
• Unexpected effects that may appear with longer duration or broader use

Longer trials and larger Phase 3 populations are where rare or delayed effects become clearer.

When could PP405 realistically be available?

Drug timelines vary. Even with Phase 3 planned, availability depends on:
successful Phase 3 outcomes, manufacturing scale-up, FDA review, and labeling decisions.
If everything goes well, it still typically takes multiple years from Phase 3 initiation to approval and rollout.

Can PP405 be combined with PRP, exosomes, or TR6™?

There’s a reasonable future case for combination approaches because they target different bottlenecks:
metabolic activation (PP405) + inflammatory modulation + scalp environment + vascular support.
However, until PP405 is approved and combination studies are done, any combination guidance would be speculative.

Today, many patients pursue a staged strategy: optimize the scalp environment and follicle health now (e.g., TR6™, PRP/exosomes where appropriate),
and reassess investigational options as stronger data emerge.

What should I do right now if I’m worried about hair loss?

• Get a diagnosis: confirm androgenetic alopecia vs shedding, inflammation, scarring alopecia, or nutritional/medical causes.
• Stabilize first: early action typically preserves more hair and improves any regrowth response.
• Choose a plan you can sustain: hair restoration is usually a long-term strategy, not a one-time event.
• Consider comprehensive options: medical therapies, regenerative protocols, and surgical artistry when appropriate.

If you’d like a personalized assessment, you can start with our consultation page to review your stage of loss and options.

Quick Disclaimer

This FAQ is educational and not medical advice. PP405 is investigational and not FDA-approved. Treatment choices should be individualized with a qualified clinician.

Citations

1. Flores A, Schell J, Krall AS, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol. 2017;19(9):1017-1026. doi:10.1038/ncb3575
2. Pelage Pharmaceuticals. Announces Positive Phase 2a Clinical Trial Results for PP405. Jun 17, 2025. Link
3. Pelage Pharmaceuticals. Announces $120 Million Series B Financing. Oct 15, 2025. Link
4. ClinicalTrials.gov. NCT06393452: Safety, Pharmacokinetics and Efficacy of PP405 in Adults with Androgenetic Alopecia. Link
5. DuBois J, et al. Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial. (PMC). Link
6. Aclaris Therapeutics. Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints. Link
7. Eli Lilly. FDA approves Olumiant (baricitinib) for severe alopecia areata. Jun 13, 2022. Link
8. Pfizer. FDA approves Litfulo (ritlecitinib) for severe alopecia areata (12+). Jun 23, 2023. Link
9. Veradermics. Completes enrollment / advances VDPHL01 in Phase 2/3. Dec 11, 2025. Link
10. Eirion Therapeutics. First-in-man clinical trial results for ET-02. Jan 8, 2025. Link
11. Amplifica. AMP-303 study update. Sep 30, 2024. Link
12. ClinicalTrials.gov. NCT03742518: SM04554 solution for AGA. Link